Oncology
2 drugs are in development for Metastatic Pancreatic Ductal Adenocarcinoma.
- Companies
- 2
- Clinical trials
- 15
BioSniper AIPage evidence connected
Prepared research question
Which programs lead the Metastatic Pancreatic Ductal Adenocarcinoma pipeline—and what evidence could change the picture?
Run cited research
Traceable citations · Unknowns marked
Drug Pipeline by Phase
Phase 1(1)
Phase 1/Phase 2(1)
| Drug | Company |
|---|---|
| ERAS-007 | Erasca, Inc. (ERAS) |
About this indication
Metastatic Pancreatic Ductal Adenocarcinoma context
Oncology·MeSH: Pancreatic Neoplasms (D010190)
Narrower concept of MeSH descriptor Pancreatic Neoplasms
Frequently asked questions
How many drugs are in development for Metastatic Pancreatic Ductal Adenocarcinoma?
BioSniper tracks 2 drugs in development for Metastatic Pancreatic Ductal Adenocarcinoma across 2 companies.
How many clinical trials target Metastatic Pancreatic Ductal Adenocarcinoma?
There are 15 clinical trials targeting Metastatic Pancreatic Ductal Adenocarcinoma tracked by BioSniper.